Company Drug

Fosun Pharma’s Tenapanor (Vteglea) Issues First China Prescription – NHE3 Inhibitor Targets Hyperphosphatemia in Dialysis Patients

By Fineline Cube #Fosun Pharmaceutical #HKG: 2196 #Market launch #SHA: 600196

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced the first prescription issuance for Tenapanor (trade name: Vteglea) in China, marking the commercial launch of the NHE3 inhibitor for serum phosphorus control in dialysis patients with chronic kidney disease (CKD). Licensed from Ardelyx, Inc. in December 2017, the drug received NMPA approval in February 2025 for patients with inadequate response or intolerance to phosphate binders, expanding Fosun’s nephrology portfolio into the hyperphosphatemia market serving China’s 400,000+ dialysis population.

Commercial Launch Milestone

ElementDetail
ProductTenapanor (Vteglea)
Drug ClassIntestinal sodium/hydrogen exchanger 3 (NHE3) inhibitor
MechanismTightens intercellular connections → reduces paracellular phosphate absorption → lowers blood phosphorus
Indication (China)Control serum phosphorus in CKD dialysis patients (inadequate response/intolerance to phosphate binders)
License OriginArdelyx, Inc. (U.S.) – December 2017 agreement
NMPA ApprovalFebruary 2025
First Prescription10 Mar 2026
MarketerShanghai Fosun Pharmaceutical (SHA: 600196, HKG: 2196)

Regulatory History & Global Approvals

RegionIndicationApproval DateStatus
U.S.Irritable bowel syndrome with constipation (IBS-C)September 2019Approved (Ibsrela brand)
Hong KongIBS-CNovember 2023Approved
U.S.Hyperphosphatemia in CKD dialysis (add-on to binders)October 2023Approved (Xphozia brand)
ChinaHyperphosphatemia in CKD dialysisFebruary 2025Approved (Vteglea brand)
Commercial LaunchChina hyperphosphatemiaMarch 2026First prescription issued

Market Context & Strategic Value

FactorImplication
China CKD Burden100+ million CKD patients; 400,000+ on dialysis; hyperphosphatemia prevalence >80%
Standard of CarePhosphate binders (calcium acetate, sevelamer, lanthanum) – adherence challenges, GI side effects, pill burden
Tenapanor DifferentiationOral small molecule; novel mechanism vs. binders; reduces pill burden; addresses binder intolerance/resistance
Fosun Portfolio FitComplicates nephrology franchise (HLX316 in development); leverages hospital dialysis center relationships
Pricing StrategyPremium positioning justified by mechanism novelty; NRDL negotiation anticipated 2026-2027

Competitive Landscape

CompetitorProductMechanismChina StatusTenapanor Advantage
SanofiRenvela (sevelamer)Phosphate binder (resin)Generic availableNovel mechanism; reduced GI side effects
FreseniusVelphoro (sucroferric oxyhydroxide)Iron-based phosphate binderApprovedOral convenience; different pathway
AkebiaAuryxia (ferric citrate)Iron-based binder + phosphate binderNot in ChinaFirst-in-class NHE3 mechanism in market
Ardelyx/FosunTenapanorNHE3 inhibitorLaunched (March 2026)Unique MOA; addresses unmet need in binder failures

Clinical Rationale & Mechanism

ParameterTenapanor Mechanism
TargetNHE3 on intestinal epithelial cells
ActionInhibits sodium/hydrogen exchange → tightens tight junctions
Phosphate EffectReduces paracellular (between-cell) phosphate absorption – primary intestinal phosphate uptake route
Serum PhosphorusDose-dependent reduction; additive to binder therapy
GI TolerabilityDiarrhea most common AE; generally manageable vs. binder GI burden

Forward-Looking Priorities

  • 2026 Launch: Dialysis center penetration; nephrologist education; patient identification (binder failures)
  • NRDL Negotiation: 2026-2027 national reimbursement list inclusion critical for volume expansion
  • Label Expansion: Potential IBS-C indication filing in China; dual-market revenue potential
  • Combination Studies: Tenapanor + binders vs. tenapanor monotherapy head-to-head data generation

Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercial launch performance, reimbursement negotiations, and market penetration for tenapanor in China. Actual results may differ due to competitive dynamics with phosphate binders, pricing regulations, and patient adoption patterns.-Fineline Info & Tech

Related Post

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Fineline Cube
Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Fineline Cube
Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Fineline Cube

You Missed

Company Deals

Eli Lilly Partners with WHO Foundation on Global Obesity Health Systems – $1.68 Million Commitment Through 2029

Company Drug

J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Company Drug

Abbisko’s ABSK061 Wins FDA Rare Pediatric Disease Designation – FGFR2/3 Inhibitor Targets Achondroplasia

Company Drug

Zelgen’s Zesuning Launches Nationwide – First China-Approved Recombinant TSH for Thyroid Cancer Follow-Up